CD33 and acute myeloid leukemia: MSCs engineered to express CD33-CD3 bispecific antibodies prevent the establishment of AML in a NOD/SCID IL2Rγ−/− (NSG) mouse model and retargeting of autologous T-cells towards blasts obtained from AML patients [232].